Avidity Biosciences Overview
Latest P/E ratio for Avidity Biosciences: -2.32 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-2.32
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, RNA shows a P/E ratio of -2.32. That is below the Healthcare sector average of 25.3. Scroll down for historical charts and peer comparison views.
The Healthcare sector average P/E ratio is about 25.3. Avidity Biosciences is at -2.32, which is lower that average. That is roughly 109.2% below the sector mean. Use the comparison chart on this page to see how RNA stacks up against individual peers as well.
Investors watch RNA's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Avidity Biosciences's latest reading is -2.32. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has Avidity Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently -2.32) with ownership activity and broader fundamentals.
The Healthcare average P/E ratio is about 25.3, while RNA is at -2.32. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
